A tumour’s necrotic core contains factors that appear to promote metastasis, or the seeding of tumour cells throughout the body, according to a new study in rats by researchers at Fred Hutchinson Cancer Center.
Researchers hope their findings, which were published in the journal Proceedings of the National Academy of Sciences, lead to a better understanding of how to cure metastatic, or stage 4 cancers, which are treatable but not curable.
“Tumor necrotic cores are a fairly common phenomenon, but they haven’t been linked to cancer metastasis until recently,” said lead author Ami Yamamoto, a Fred Hutch graduate student working in the Cheung Lab. “Our research put together observations other people have made into the specific context of breast cancer metastasis. Our work shows a link between necrosis, circulating tumour cells and cancer metastasis.”
What is a dead zone
Necrotic cores are tumours that are dying from the inside out, and they make for a perfect environment for cancer to spread.
“Dead zones of tumours have leaky blood vessels, hypoxia or low levels of oxygen and the recruitment of immune cells, some of which have been shown to help cancer cells spread,” Yamamoto said. “What we think is happening is that the necrotic core is mostly a dead zone, but it also has some surviving tumour cells that help cancer disseminate in the body.”
Surgeons, pathologists, radiologists, clinicians and researchers often come across necrotic cores in their line of work and they’re usually not a good sign.
“Necrosis is a clinical finding seen in aggressive tumours that grow quickly,” said Fred Hutch physician-researcher Kevin Cheung, MD, senior author of the study. “When we see it in a patient’s biopsy, it means this is a dangerous tumour that needs to be treated aggressively.”
But necrosis isn’t only something seen in large, late-stage tumours, Cheung said. It can happen in early-stage and small tumours too.
A protein linked to necrosis and cancer spread
The Fred Hutch team developed a new rat model of breast cancer metastasis to study the necrotic core of tumours. Over several weeks, Yamamoto tracked the progression of circulating tumour cells (CTCs), which is a measure of whether the cancer cells are escaping into the bloodstream to spread throughout the body. They found zero CTCs at the first two time points examined (after 13 and 17 days), but that changed by the fourth time point at 27 days.
“Suddenly, we found hundreds of CTCs,” Yamamoto said. She linked the increase in cancer cells with when the primary tumour developed a large central area of necrosis.
Further investigation showed a stark difference in gene expression between the necrotic and the non-necrotic regions of the tumour.
“We found that a gene which encodes angiopoietin-like 7, a secreted protein, was the most enriched tumour-derived gene in the necrotic and regions next to necrotic regions of the tumour,” Yamamoto said.
The researchers found that this single protein, angiopoietin-like-7, remodels the tumour microenvironment, somehow encouraging the tumour cells to grow past their nutrient limits, undergo necrosis and start spreading to other parts of the body.
“This was a surprise,” Cheung said. “We thought necrosis was entirely unregulated, not something you can control.”
Yamamoto then did experiments to see how controlling the protein would impact necrosis.
“When we suppressed the expression of this protein in the tumours, there was a dramatic reduction of necrotic tumour area,” Yamamoto said. “Suppression of angiopoietin-like 7, or A-7, also reduced circulating tumour cells to almost zero and reduced distant metastases and dilated large blood vessels.”
Yamamoto said their research not only showed A-7 regulates the development of central necrosis in the primary tumour, but also the development of dilated blood vessels which could be helping the dissemination of circulating tumour cells and metastasis.
A potential new target for treatment
Beyond the surprise of such an important mechanism for necrosis, these findings unveiled the potential for a new targeted treatment for patients.
“Our ultimate goal is to develop a therapeutic antibody against A-7 that will prevent or reduce metastasis in patients with metastatic breast cancer,” she said.
Toward that end, the team has already come up with over 200 candidates for an anti-A-7 antibody but needs to screen through all of them to see which ones do the best job of blocking the function. Cheung said he and his team also want to analyze the data of large patient cohorts to better understand the role of necrosis in the tumour and the risk of metastatic dissemination.
“Some patients have evidence of markers of necrosis in their blood,” he said. “That suggests this is potentially happening not just in preclinical models but in patients.”
Cheung and Yamamoto also want to delve into the unanswered questions that remain.
“Before we started this, we probably considered the necrotic core to be the least interesting part of the tumour,” Cheung said. “We’re now confident the inside is a really interesting place for studying the source of metastatic cancer. There’s more cancer biology there that awaits.”